PP2A inhibition leads to phosophorylation and activation of PLK and allows for enhanced anticancer activity of chemotherapy directed against a GBM cell line [37] as well as a pheochromocytoma cell line [38]. The gene discussed is PLK1; the disease is pheochromocytoma.